COMMUNIQUÉS West-GlobeNewswire
-
Major shareholder announcement - BlackRock, Inc.
05/10/2026 -
FDA Clears Motivista (CT-155), the First Authorized Treatment for Negative Schizophrenia Symptoms
05/10/2026 -
Cerene® Cryotherapy Brings Free Mother-Daughter Period Education Brunch to Indianapolis Area
05/10/2026 -
Genmab and AbbVie Announce Epcoritamab in Combination with R-CHOP Demonstrates Statistically Significant Improvement in Progression-Free Survival in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma
05/10/2026 -
Baylor Genetics Selected as the Lead Sequencing Partner for Florida’s Sunshine Genetics Pilot Program Launch
05/10/2026 -
Frederick Breathe Free Celebrates Dr. Jamie Oberman’s Recognition as a 2026 Castle Connolly Top Doctor
05/10/2026 -
Zealand Pharma – Completion of share buy-back program and related transactions (week 40 and 41, 2026)
05/10/2026 -
Global Alzheimer's Platform Foundation Names New Medical Director at Tampa Research Site
05/10/2026 -
Declaration of shares and voting rights - Status as of September 30, 2026
05/10/2026 -
Déclaration d’actions et de droits de vote - Statut au 30 septembre 2026
05/10/2026 -
Efficacy of aprocitentan in patients across the cardiometabolic disease spectrum including obesity to be presented at AHA Hypertension
05/10/2026 -
Sironax Named to Fierce Biotech’s “Fierce 15” List of the Most Innovative and Promising Private Biotechs of 2026
05/10/2026 -
Curia Invests $28 Million in Sterile API Manufacturing
05/10/2026 -
Curia investit 28 millions de dollars dans la fabrication d’API stériles
05/10/2026 -
Pistol and Paris Launches Vanquish Medical Providing Access and Serving Medical Cannabis Patients Across Canada
05/10/2026 -
Capricor Therapeutics Presents Positive HOPE-3 Open-Label Extension Data on Upper Limb Function in Duchenne Muscular Dystrophy at 2026 World Muscle Society Congress
05/10/2026 -
Kymanox Launches KymaBridge, an Intelligence Platform Connecting Pharma and Biotech Innovators with Drug Delivery Device Technologies
05/10/2026 -
Medicenna Announces Oral Presentation of Topline Data from the Phase 1/2 ABILITY-1 Study of MDNA11 at SITC 2026
05/10/2026 -
Freya Biosciences named as one of Fierce Biotech’s “Fierce 15” for 2026
05/10/2026
Pages